Description
A drug used to treat non-small cell lung cancer that has spread to other parts of the body and has certain mutations (changes) in the EGFR gene. It is used in patients whose cancer has not already been treated with other anticancer therapy. It is also being studied in the treatment of other types of cancer. Gefitinib blocks certain proteins made by the EGFR gene, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Gefitinib is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Iressa and ZD1839.
Gefitinib is approved to treat: Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations. Gefitinib is also being studied in the treatment of other types of cancer.
Oncology medicine manufacturer in India
List of Indian Pharma Manufacturer companies name are Astrazeneca, Glenmark, Hetero Healthcare, Cipla, Panacea Biotec, Metta Life Sciences, R.P.G Life Sciences, Bdr Pharmaceuticals, Halsted Pharma
